Head-to-head evidence
DA-302168S vs HRS-7535
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1 receptor · full Obesity pipeline
DA-302168S
Developed by Chendu DIAO Pharmaceutical Group
NCT06953063 · Phase 2 · completed
The trial was randomized, quadruple-blind, placebo-controlled, and enrolled 250 participants, with percentage change in body weight as a clinical primary endpoint. However, results are not posted, so it is not possible to determine whether the primary comparison was met; the available evidence therefore supports a moderate grade rather than a strong one.
Next expected readout: July 2027 · NCT07629544 (registry estimate)
HRS-7535
Developed by Kailera Therapeutics under a licence from Jiangsu Hengrui Pharmaceuticals
NCT06904105 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial (n=556). The primary endpoint, percent weight change at week 44, was met: participants lost 9.5% (120 mg) and 10.9% (180 mg) of body weight versus 2.5% with placebo.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: December 2026 · NCT06820099 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: DA-302168S's landscape · HRS-7535's landscape